一、文章
1. Yijiao Chen#, Xudong Liu#, Jiongming Chen, Liwen Kuang, Nan Zhang, Danyang Li, Dan Zhao, Dongmei Xue, Juan Lei, Jiangang Zhang, Yongsheng Li*, Lei Wu*. Macrophage CCL7 promotes resistance to immunotherapy for colorectal cancer by regulating the infiltration of macrophages and CD8+ T cells. J. Immunother. 2025, 12(11). (IF: 10.9，最后通讯)
2. Liwen Kuang; Lei Wu*; Yongsheng Li*. Extracellular vesicles in tumor immunity: mechanisms and novel insights. Molecular Cancer. 2025, 24(45). (IF: 33.9，共同通讯)
3. Dan Zhao Lei Wu*; Yongsheng Li*. Targeting lipid metabolism to enhance cancer immunotherapy BBA-REV CANCER 2025, 1880(5). (IF: 8.316，共同通讯)
4. Jiongming, Chen; Lei, Wu*; Yongsheng, Li*. FGL1 and FGL2: emerging regulators of liver health and disease. Biomark Res. 2024 May 31;12(1):53. (IF: 9.6，共同通讯)
5. Chen Yijiao; Li Yongsheng*; Wu Lei*. Protein S-palmitoylation modification: implications in tumor and tumor immune microenvironment. Frontiers in Immunology. 2024, 15. (IF: 7.3，最后通讯)
6. Wu Lei; Liu Xudong; Lei Juan; Zhang Nan; Zhao Huakan; Zhang Jiangang; Deng Huan; Li Yongsheng*. Fibrinogen-like protein 2 promotes tumor immune suppression by regulating cholesterol metabolism in myeloid-derived suppressor cells. J. Immunother. 2023, 12(11). (IF: 10.9，一作)
7. Wen Jiaqi; Yang Shuai; Yan Guifang; Lei Juan; Liu Xudong; Zhang Nan; Zhang Jiangang; Deng Huan; Wu Lei*; Li Yongsheng*. Increased OIT3 in macrophages promotes PD-L1 expression and hepatocellular carcinogenesis via NF-κB signaling. Experimental Cell Research. 2023, 428(2): 113651. (IF: 4.145，共同通讯)
8. Wu L, Xu Y, Zhao H, Zhou Y, Chen Y, Yang S, Lei J, Zhang J, Wang J, Wu Y(*), Li Y(*). FcγRIIB potentiates differentiation of myeloid-derived suppressor cells to mediate tumor immunoescape. Theranostics. 2022 Jan 1, 12 (2): 842-858. (IF: 11.556，一作)
9. Wu L(#), Zhang X(#), Zheng L(#), Zhao H, Yan G, Zhang Q, Zhou Y, Lei J, Zhang J, Wang J, Xin R, Jiang L, Peng J, Chen Q, Lam S, Shui G, Miao H, Li Y*. RIPK3 orchestrates fatty acid metabolism in tumor-associated macrophages and hepatocarcinogenesis. Cancer Immunol Res. 2020 May;8(5):710-721. (IF：12.06，一作)
10. Wu Lei(#), Xu Yanquan(#), Zhao Huakan(#), Li Yongsheng(*). RNase T2 in Inflammation and Cancer: Immunological and Biological Views. Front Immunol. 2020; 13(11):1554. (IF：7.561，一作)
11. Zhao Huakan(#), Wu Lei(#), Yan Guifang(#), Chen Yu(#), Zhou Mingyue(#), Wu Yongzhong(*), Li Yongsheng(*). Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6(1):263 (IF:38.187; 共一排2)
12. Zhang X(#), Wu L(#), Xu Y, Yu H, Chen Y, Zhao H, Lei J, Zhou Y, Zhang J, Wang J, Peng J, Jiang L, Sheng H, Li Y(*). Microbiota-derived SSL6 enhances the sensitivity of hepatocellular carcinoma to sorafenib by down-regulating glycolysis. Cancer Lett. 2020 Jul 1;481:32-44. (IF: 8.679; 共一排2)
13. Zhou Y(#), Lei J(#), Xie Q(#), Wu L(#), Jin S, Guo B, Wang X, Yan G, Zhang Q, Zhao H, Zhang J, Zhang X, Wang J, Gu J, Liu X, Ye D, Miao H*, Serhan CN(*), Li Y(*). Fibrinogen-like protein 2 controls sepsis catabasis by interacting with resolvin Dp5. Sci Adv. 2019, 5: aax0629 (IF: 14.14; 共一排4)
二、承担和参与的科学研究项目
[1]国家自然科学基金面上项目，MS4A7激活CD36-Rab5-PPARγ通路促进肿瘤相关巨噬细胞免疫抑制功能的分子机制研究（82572105）；项目负责人（2026.1-2029.12）
[2]国家自然科学基金面上项目，FcγRIIB激活脂肪酸代谢诱导肿瘤相关巨噬细胞向M2型极化的分子机制研究（82271885）；项目负责人（2023.1-2026.12）
[3]国家自然科学基金青年项目，RIPK3通过FoxO1-PDK2信号通路诱导TAMs向M1型极化的分子机制研究（81901624）；项目负责人（2020.1-2022.12）
[4] 重庆市中青年医学高端人才项目；项目负责人（2023.6-2026.6）
[5] 重庆市博士后留渝科研资助；项目负责人（2020.7-2024.6）
[6] 重庆市自然科学基金面上项目，肿瘤相关巨噬细胞来源的CCL7促进结直肠癌侵袭和转移的作用机制研究（2024NSCQ-KJFZMSX0059）；项目负责人（2024.12-2027.12）
[7] 重庆市自然科学基金面上项目，肿瘤来源的GMCSF通过Sp1/Fgl2-FCGRIIB通路诱导MDSC免疫抑制功能的分子机制研究（cstc2021jcyj-msxmX0111）；项目负责人（2021.10-2024.09）
三、相关奖励与荣誉
[1] 2025年中国抗癌协会科技奖二等奖
[2] 2024 年度重庆市自然科学二等奖
